Study Shows Quantose IR(TM) Measures Insulin Sensitivity

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Study Shows Quantose IR(TM) Measures Insulin Sensitivity Better Than A1C Test for Prediabetes

RESEARCH TRIANGLE PARK, N.C., March 18, 2015 (GLOBE NEWSWIRE) -- Metabolon, Inc. announced results from a study using samples from the long-term ACT NOW diabetes prevention study of prediabetic subjects. Analysis showed that its Quantose IR™ test tracked changes in insulin sensitivity better than the hemoglobin A1C test in patients treated with the insulin sensitizer, pioglitazone. These results were recently published online by the Journal of Clinical Endocrinology & Metabolism .

A chart accompanying this release is available at http://media.globenewswire.com/cache/31471/file/32670.pdf

In the ACT NOW study, patients with impaired glucose tolerance were randomized to pioglitazone (45mg/day) or placebo and followed for an average of 2.4 years. Researchers conducted a retrospective study using samples from 210 subjects treated with pioglitazone to assess the clinical validity of Quantose IR for monitoring changes in insulin sensitivity. Quantose IR tracked insulin sensitivity and glucose tolerance, with a significant 29 percent improvement in Quantose IR scores in pioglitazone-treated patients. In contrast, A1C scores worsened slightly in the same subjects.

Insulin resistance is a root cause of prediabetes, type 2 diabetes, high blood pressure, cardiovascular disease and other health conditions. "Identifying and managing insulin resistance play significant roles in guiding interventions to delay or prevent these conditions," said study investigator Ralph A. DeFronzo, MD, Texas Diabetes Institute, University of Texas Health Science Center. "Until now, though, there were no simple tests to easily identify insulin resistance. Quantose IR appears to be a useful tool to identify and monitor therapy in insulin-resistant patients because of its strong correlation with improved insulin sensitivity and ease of use."

"The Quantose IR test will help clinicians implement the recently issued American Diabetes Association intervention guidelines for prediabetes," said Eric Button, senior vice president of diagnostics for Metabolon. "While A1C is an excellent test for measuring changes in glucose, insulin resistance may occur more than 10 years before changes in glucose levels can be seen in a patient. Earlier clinical intervention along the continuum may prevent the progression to type 2 diabetes and other serious health problems."

About Quantose IR

Quantose IR is a laboratory-developed test (LDT) based on insulin and three non-glycemic biomarkers. It is the first and only test clinically developed and validated to measure insulin resistance. It is a simple, easy-to-use test requiring only a single, fasted blood draw. Clinicians may call 919.572.1711 for more information about Quantose IR.

About Metabolon

Metabolon, Inc. is the world's leading life sciences company focused on metabolomics – an integrative, powerful phenotyping technology for assessing health. Its proprietary platforms and informatics systems are delivering biomarker discoveries, innovative diagnostic tests, breakthroughs in personalized medicine, and robust partnerships in genomics-based health initiatives. Metabolon's expertise is also accelerating research and product development for more than 650 clients across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 3,500 independent and collaborative studies, resulting in over 400 peer-reviewed publications. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter .

Cautionary Note about Forward-Looking Statements

The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon's results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon's metabolomic services; Metabolon's and its distributors' ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon's intellectual property portfolio; Metabolon's history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon's ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.

Media Contact: Robin Fastenau Vice President, Corporate Communications 919.595.2201

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 479

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading

Top 5 Most Recently Viewed Articles

Day One Biopharmaceuticals Set to Announce Q4 Earnings Soon

Updated Category News Views 100

Day One Biopharmaceuticals Announces Financial Results Call Day One Biopharmaceuticals (NASDAQ: DAWN) is making new strides in the biopharmaceutical sector, focusing on therapies that target significant health challenges affecting individuals of all ages. The company has scheduled a live conference call for stakeholders, during which they will release their financial...

Continue Reading
Celebrating Daniel P. O'Toole's Prestigious Legal Achievement

Updated Category News Views 208

Daniel P. O'Toole Celebrated as 'Lawyer of the Year' Daniel P. O'Toole, managing partner of the renowned Block O'Toole & Murphy, has been bestowed with the prestigious 2026 'Lawyer of the Year' honor in Personal Injury Litigation – Plaintiff by Best Lawyers. This recognition, awarded only to one attorney per year in each specialty and area, underscores the remarkable...

Continue Reading
Jeffrey Pribor Sells Options for $535K, Insights from INSW

Updated Category News Views 180

Key Insider Activity in International Seaways Recently, a significant stock option exercise by Jeffrey Pribor, who serves as SVP & CFO at International Seaways (NYSE: INSW), was made public through a recent SEC filing. This exercise is a notable insider transaction, which can provide insights into the company’s financial activities. What Transpired with the Stock...

Continue Reading
Join Elkem ASA in Shaping a Sustainable Future Today

Updated Category News Views 221

Elkem ASA Annual General Meeting in 2025 Elkem ASA is hosting its annual general meeting on 30 April 2025. This gathering will take place online at 09:30 (CEST) via the Lumi AGM platform, providing a convenient digital experience for all shareholders. The meeting will include a live webcast and feature electronic voting, allowing participants to engage seamlessly from any...

Continue Reading
Industrial Safety Gates Market Growth Driven by Innovative Features

Updated Category News Views 175

Industrial Safety Gates Market Growth Driven by Innovative Features The industrial safety gates market is on the rise, with projections estimating growth of USD 140.9 million from 2024 to 2028. This increase is propelled by key features such as self-closing mechanisms and ongoing advancements in artificial intelligence (AI). Companies operating within this market are...

Continue Reading